Oncology is one of the most critical partitions of medicine, as it deals with one of the most dangerous diseases in human history: Cancer.Oncology directly studies tumors, cancers, as well as other researching topics like aging, cells, and other subjects.Because of the importance of this part of the medical industry, many types of research around the world rely on newsletters and magazines to stay up to date to the latest discoveries in that front, and Oncotarget is one of them.In the online atmosphere, Oncotarget is the number 1 choice among doctors and scientists in Oncology as the primary online newsletter to keep them updated on what is happening around the globe and what are the latest cancer news regarding different fronts.
Oncotarget actually does not only cover oncology, but many other subjects that have something to do with cellular level, diseases, aging, and other anatomy-related subjects that can significantly improve the perception of the followers of the page regarding these topics.In fact, the website became so popular that they increased their publication rate and acquired more experts to the staff in order to post more news every week with higher efficiency and quality.The best of Oncotarget: It is entirely free and available to everyone.Because scientific newsletters and magazines can be incredibly expensive, primarily because they post news that are updated and can’t be found anywhere else, Oncotarget has an edge because they are also modern, up-to-date and the staff does not charge a single dime.
Many companies and researchers are turning to the Oncotarget website to directly ask publishers to submit their researches, studies, discoveries, news, and observations. IntegraGen, the company that studies the transformation of genomic information and data in order to be investigated by oncology in general, is turning to Oncotarget to post their latest news and updates because of its reach and influence among oncologists. IntegraGen will be covering their results analysis of the famous miR-31-3p expression in many tumor samples that were obtained from patients who experienced them and were able to overcome the expression or show different reaction signs.If you want to be updated on that research, make sure to visit Oncotarget and find out more about the subject.